Hodgkin lymphoma version 1.2017

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip Jay Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. KenkreNadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N. Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, Hema Sundar

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

Original languageEnglish (US)
Pages (from-to)608-638
Number of pages31
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Hodgkin Disease
Combined Modality Therapy
Poisons
Therapeutics
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., ... Sundar, H. (2017). Hodgkin lymphoma version 1.2017. JNCCN Journal of the National Comprehensive Cancer Network, 15(5), 608-638. https://doi.org/10.6004/jnccn.2017.0064

Hodgkin lymphoma version 1.2017. / Hoppe, Richard T.; Advani, Ranjana H.; Ai, Weiyun Z.; Ambinder, Richard F.; Aoun, Patricia; Bello, Celeste M.; Benitez, Cecil M.; Bernat, Karl; Bierman, Philip Jay; Blum, Kristie A.; Chen, Robert; Dabaja, Bouthaina; Forero, Andres; Gordon, Leo I.; Hernandez-Ilizaliturri, Francisco J.; Hochberg, Ephraim P.; Huang, Jiayi; Johnston, Patrick B.; Kaminski, Mark S.; Kenkre, Vaishalee P.; Khan, Nadia; Maloney, David G.; Mauch, Peter M.; Metzger, Monika; Moore, Joseph O.; Morgan, David; Moskowitz, Craig H.; Mulroney, Carolyn; Poppe, Matthew; Rabinovitch, Rachel; Seropian, Stuart; Smith, Mitchell; Winter, Jane N.; Yahalom, Joachim; Burns, Jennifer; Ogba, Ndiya; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 5, 01.05.2017, p. 608-638.

Research output: Contribution to journalReview article

Hoppe, RT, Advani, RH, Ai, WZ, Ambinder, RF, Aoun, P, Bello, CM, Benitez, CM, Bernat, K, Bierman, PJ, Blum, KA, Chen, R, Dabaja, B, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Hochberg, EP, Huang, J, Johnston, PB, Kaminski, MS, Kenkre, VP, Khan, N, Maloney, DG, Mauch, PM, Metzger, M, Moore, JO, Morgan, D, Moskowitz, CH, Mulroney, C, Poppe, M, Rabinovitch, R, Seropian, S, Smith, M, Winter, JN, Yahalom, J, Burns, J, Ogba, N & Sundar, H 2017, 'Hodgkin lymphoma version 1.2017', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 5, pp. 608-638. https://doi.org/10.6004/jnccn.2017.0064
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM et al. Hodgkin lymphoma version 1.2017. JNCCN Journal of the National Comprehensive Cancer Network. 2017 May 1;15(5):608-638. https://doi.org/10.6004/jnccn.2017.0064
Hoppe, Richard T. ; Advani, Ranjana H. ; Ai, Weiyun Z. ; Ambinder, Richard F. ; Aoun, Patricia ; Bello, Celeste M. ; Benitez, Cecil M. ; Bernat, Karl ; Bierman, Philip Jay ; Blum, Kristie A. ; Chen, Robert ; Dabaja, Bouthaina ; Forero, Andres ; Gordon, Leo I. ; Hernandez-Ilizaliturri, Francisco J. ; Hochberg, Ephraim P. ; Huang, Jiayi ; Johnston, Patrick B. ; Kaminski, Mark S. ; Kenkre, Vaishalee P. ; Khan, Nadia ; Maloney, David G. ; Mauch, Peter M. ; Metzger, Monika ; Moore, Joseph O. ; Morgan, David ; Moskowitz, Craig H. ; Mulroney, Carolyn ; Poppe, Matthew ; Rabinovitch, Rachel ; Seropian, Stuart ; Smith, Mitchell ; Winter, Jane N. ; Yahalom, Joachim ; Burns, Jennifer ; Ogba, Ndiya ; Sundar, Hema. / Hodgkin lymphoma version 1.2017. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 5. pp. 608-638.
@article{89cac2f304744ae8b85620617bfcabe1,
title = "Hodgkin lymphoma version 1.2017",
abstract = "This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.",
author = "Hoppe, {Richard T.} and Advani, {Ranjana H.} and Ai, {Weiyun Z.} and Ambinder, {Richard F.} and Patricia Aoun and Bello, {Celeste M.} and Benitez, {Cecil M.} and Karl Bernat and Bierman, {Philip Jay} and Blum, {Kristie A.} and Robert Chen and Bouthaina Dabaja and Andres Forero and Gordon, {Leo I.} and Hernandez-Ilizaliturri, {Francisco J.} and Hochberg, {Ephraim P.} and Jiayi Huang and Johnston, {Patrick B.} and Kaminski, {Mark S.} and Kenkre, {Vaishalee P.} and Nadia Khan and Maloney, {David G.} and Mauch, {Peter M.} and Monika Metzger and Moore, {Joseph O.} and David Morgan and Moskowitz, {Craig H.} and Carolyn Mulroney and Matthew Poppe and Rachel Rabinovitch and Stuart Seropian and Mitchell Smith and Winter, {Jane N.} and Joachim Yahalom and Jennifer Burns and Ndiya Ogba and Hema Sundar",
year = "2017",
month = "5",
day = "1",
doi = "10.6004/jnccn.2017.0064",
language = "English (US)",
volume = "15",
pages = "608--638",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Hodgkin lymphoma version 1.2017

AU - Hoppe, Richard T.

AU - Advani, Ranjana H.

AU - Ai, Weiyun Z.

AU - Ambinder, Richard F.

AU - Aoun, Patricia

AU - Bello, Celeste M.

AU - Benitez, Cecil M.

AU - Bernat, Karl

AU - Bierman, Philip Jay

AU - Blum, Kristie A.

AU - Chen, Robert

AU - Dabaja, Bouthaina

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hochberg, Ephraim P.

AU - Huang, Jiayi

AU - Johnston, Patrick B.

AU - Kaminski, Mark S.

AU - Kenkre, Vaishalee P.

AU - Khan, Nadia

AU - Maloney, David G.

AU - Mauch, Peter M.

AU - Metzger, Monika

AU - Moore, Joseph O.

AU - Morgan, David

AU - Moskowitz, Craig H.

AU - Mulroney, Carolyn

AU - Poppe, Matthew

AU - Rabinovitch, Rachel

AU - Seropian, Stuart

AU - Smith, Mitchell

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Burns, Jennifer

AU - Ogba, Ndiya

AU - Sundar, Hema

PY - 2017/5/1

Y1 - 2017/5/1

N2 - This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

AB - This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

UR - http://www.scopus.com/inward/record.url?scp=85019066211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019066211&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0064

DO - 10.6004/jnccn.2017.0064

M3 - Review article

C2 - 28476741

AN - SCOPUS:85019066211

VL - 15

SP - 608

EP - 638

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -